M3 Muscarinic receptor activation reduces hepatocyte lipid accumulation via CaMKKβ/AMPK pathway.

  title={M3 Muscarinic receptor activation reduces hepatocyte lipid accumulation via CaMKK$\beta$/AMPK pathway.},
  author={Ravirajsinh N. Jadeja and Xin Chu and Craig Wood and Manuela Bartoli and Sandeep Khurana},
  journal={Biochemical pharmacology},
Previously, we reported that hepatic muscarinic receptors modulate both acute and chronic liver injury, however, the role of muscarinic receptors in fatty liver disease is unclear. We observed in patients who underwent weight loss surgery, a decrease in hepatic expression of M3 muscarinic receptors (M3R). We also observed that fat loading of hepatocytes, increased M3R expression. Based on these observations, we tested the hypothesis that M3R regulate hepatocyte lipid accumulation. Incubation of… Expand
Epigenetic histone modulations of PPARγ and related pathways contribute to olanzapine-induced metabolic disorders.
It is suggested that olanzapine acted as stimuli to trigger the cascade of adipogenesis and lipogenesis through modulating hepatic histone modifications and subsequently upregulating key transcriptional factors. Expand
Murine remote ischemic preconditioning suppresses diabetic ketoacidosis by enhancing glycolysis and entry into tricarboxylic acid cycle in the liver.
Results indicated that in the IR-treated diabetic liver, energy production was promoted through acceleration of the tricarboxylic acid cycle linked with increased glucose preference rather than fatty acid under feeding conditions, suggesting that IR may be beneficial against diabetic hyperglycemia, but also ketoacidosis. Expand
Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical Differences
There seems to be a correlation between AAP’s higher clinical efficacy and increase risk of metabolic alterations, and a multidisciplinary approach combining psychoeducation and therapeutic drug monitoring (TDM) is proposed as a first-line strategy to avoid the MetS. Expand
Metformin inhibits the function of granulocytic myeloid-derived suppressor cells in tumor-bearing mice.
It is found that metformin could inhibit the accumulation and suppressive capacity of G-MDSCs, delay tumor progression and elicit Th1 and CTL responses in murine colon cancer CT-26 cell-transplanted mice, suggesting that met formin may be a potential clinical benefit for antitumor immunotherapy in tumor-bearing mice. Expand
The dosage-dependent effects of cevimeline in preventing olanzapine-induced metabolic side-effects in female rats
A dosage-dependent effect of cevimeline is suggested in ameliorating olanzapine-induced weight gain and metabolic side-effects, which supports further clinical trials using cevIMeline to control weight Gain and metabolic Side-effects caused by antipsychotic medications. Expand
AMPK and TOR: The Yin and Yang of Cellular Nutrient Sensing and Growth Control.
The evolution, structure, and regulation of the AMPK and TOR pathways and the complex mechanisms by which they interact are discussed. Expand


M1 muscarinic receptors modify oxidative stress response to acetaminophen-induced acute liver injury.
M1R modify hepatocyte responses to oxidative stress and that targeting M1R has therapeutic potential for toxic liver injury is concluded. Expand
Effects of modulating M3 muscarinic receptor activity on azoxymethane-induced liver injury in mice.
Several downstream mechanisms whereby M3R activation ameliorates toxic liver injury are identified, including Cleaved caspase-3, nitrotyrosine and BrdU immunostaining provided evidence that pilocarpine treatment reduced hepatocyte apoptosis and oxidative stress, while increasing hepatocyte proliferation. Expand
M1 Muscarinic Receptor Deficiency Attenuates Azoxymethane-Induced Chronic Liver Injury in Mice
Results indicate that following liver injury, anti-oxidant response in M1R-deficient mice attenuates hepatocyte apoptosis and reduces stellate cell activation, thereby diminishing fibrosis. Expand
Scopolamine Treatment and Muscarinic Receptor Subtype-3 Gene Ablation Augment Azoxymethane-Induced Murine Liver Injury
Chrm3 plays a critical role in the liver injury response by modulating hepatocyte proliferation and apoptosis by inhibiting postneuronal cholinergic muscarinic receptor activation with either scopolamine treatment or Chrm3 gene ablation. Expand
The M3-muscarinic acetylcholine receptor stimulates glucose uptake in L6 skeletal muscle cells by a CaMKK-AMPK-dependent mechanism.
This study demonstrates that activation of M(3) mAChRs in L6 skeletal muscle cells stimulates glucose uptake via a CaMKK-AMPK-dependent mechanism, independent of the insulin-stimulated pathway. Expand
Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease.
The transcriptional activation and repression mechanisms by PPAR α, the spectrum of target genes and chromatin-binding maps from recent genome-wide studies, are discussed, paying particular attention to PPARα-regulation of hepatic fatty acid and plasma lipoprotein metabolism during nutritional transition, and of the inflammatory response. Expand
Quantification and mechanisms of oleic acid-induced steatosis in HepG2 cells.
In the absence of exogenous inflammatory mediators, OA-induced steatosis results in a series of pathophysilogical changes in HepG2 cells, indicating direct pathogenic roles of hepatocytes in NAFLD. Expand
Muscarinic Receptor Activation of AMP-activated Protein Kinase Inhibits Orexigenic Neuropeptide mRNA Expression*
It is demonstrated that the muscarinic receptor agonist carbachol activates AMPKα1-containing complexes in the human SH-SY5Y cell line via a mechanism specific for the AMPK upstream kinase, Ca2+/calmodulin-dependent protein kinase kinase β. Expand
Roles of PPARs in NAFLD: potential therapeutic targets.
Recent findings on the pathophysiological role of PPARs in the different stages of NAFLD, from steatosis development to steatohepatitis and fibrosis, as well as the preclinical and clinical evidence for potential therapeutical use ofPPAR agonists in the treatment ofNAFLD are reviewed. Expand
AMP activated protein kinase: a next generation target for total metabolic control
  • P. Misra
  • Biology, Medicine
  • Expert opinion on therapeutic targets
  • 2008
The data suggest that AMPK may be a key player in the development of new treatments for obesity, Type 2 diabetes and the metabolic syndrome, with insight into the role of AMPK as a probable target for treatment of metabolic syndrome. Expand